Nanoimages show disruption of tubulin polymerization by chlorpyrifos oxon: implications for neurotoxicity.
Organophosphorus agents cause cognitive deficits and depression in some people. We hypothesize that the mechanism by which organophosphorus agents cause these disorders is by modification of proteins in the brain. One such protein could be tubulin. Tubulin polymerizes to make the microtubules that transport cell components to nerve axons. The goal of the present work was to measure the effect of the organophosphorus agent chlorpyrifos oxon on tubulin polymerization. An additional goal was to identify the amino acids covalently modified by chlorpyrifos oxon in microtubule polymers and to compare them to the amino acids modified in unpolymerized tubulin dimers. Purified bovine tubulin (0.1 mM) was treated with 0.005-0.1 mM chlorpyrifos oxon for 30 min at room temperature and then polymerized by addition of 1 mM GTP to generate microtubules. Microtubules were visualized by atomic force microscopy. Chlorpyrifos oxon-modified residues were identified by tandem ion trap electrospray ionization and matrix-assisted laser desorption/ionization mass spectrometry of tryptic peptides. Nanoimaging showed that low concentrations (0.005 and 0.01 mM) of chlorpyrifos oxon yielded short, thin microtubules. A concentration of 0.025 mM stimulated polymerization, while high concentrations (0.05 and 0.1 mM) caused aggregation. Of the 17 tyrosines covalently modified by chlorpyrifos oxon in unpolymerized tubulin dimers, only 2 tyrosines were labeled in polymerized microtubules. The two labeled tyrosines in polymerized tubulin were Tyr 103 in EDAANNYR of alpha tubulin, and Tyr 281 in GSQQYR of beta tubulin. In conclusion, chlorpyrifos oxon binding to tubulin disrupts tubulin polymerization. These results may lead to an understanding of the neurotoxicity of organophosphorus agents.
Grigoryan
Hasmik
H
University of Nebraska Medical Center, Eppley Institute for Cancer Research, 986805 Nebraska Medical Center, Omaha, NE 68198-6805, USA.
Lockridge
Oksana
O
D000818:Animals; D002417:Cattle; D004390:Chlorpyrifos / Q000031:analogs & derivatives* / Q000378:metabolism / Q000633:toxicity; D002800:Cholinesterase Inhibitors / Q000378:metabolism / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D006160:Guanosine Triphosphate / Q000378:metabolism; D018625:Microscopy, Atomic Force; D049329:Nanostructures; D020258:Neurotoxicity Syndromes / Q000209:etiology* / Q000378:metabolism / Q000473:pathology; D055503:Protein Multimerization; D021241:Spectrometry, Mass, Electrospray Ionization; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D053719:Tandem Mass Spectrometry; D014404:Tubulin / Q000187:drug effects* / Q000378:metabolism / Q000648:ultrastructure; D050257:Tubulin Modulators / Q000378:metabolism / Q000633:toxicity*; D014443:Tyrosine
D002800:Cholinesterase Inhibitors; D014404:Tubulin; D050257:Tubulin Modulators; D014443:Tyrosine; C009618:O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate; D006160:Guanosine Triphosphate; D004390:Chlorpyrifos